Citation Impact
Citing Papers
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
2004 StandoutScience
Plants send small RNAs in extracellular vesicles to fungal pathogen to silence virulence genes
2018 StandoutScience
The Bmi-1 oncoprotein is overexpressed in human colorectal cancer and correlates with the reduced p16INK4a/p14ARF proteins
2004
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer
2004
Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer
2016
Hallmarks of Cancer: The Next Generation
2011 Standout
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
2006 Standout
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma
2003
The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer
2007
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2011
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
2013
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
2009
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial
2010
Cardiotoxic effects of anthracycline–taxane combinations
2003
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
2013
Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1
2000 StandoutNobel
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
2008 Standout
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
2013
mTOR Signaling in Growth Control and Disease
2012 Standout
A phase II study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer
2000
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
2010
Genes that mediate breast cancer metastasis to the brain
2009 StandoutNature
Fluorouracil, Doxorubicin, and Cyclophosphamide Followed by Tamoxifen as Adjuvant Treatment for Patients with Stage IV Breast Cancer with No Evidence of Disease
2002
AKT/PKB Signaling: Navigating Downstream
2007 Standout
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy
2011
Phosphoinositide phosphatases in cell biology and disease
2010
Sirtuin-7 Inhibits the Activity of Hypoxia-inducible Factors
2013 StandoutNobel
Polycomb silencers control cell fate, development and cancer
2006
The biology and management of non-small cell lung cancer
2018 StandoutNature
Docetaxel 75 mg/m2 is Active and Well Tolerated in Patients with Metastatic or Recurrent Gastric Cancer: a Phase II Trial
2002
Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer
2006
In vivo MRI of cancer cell fate at the single‐cell level in a mouse model of breast cancer metastasis to the brain
2006
Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells
2003 Nature
Cancer Metastasis: Building a Framework
2006 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Hypoxia-induced apoptosis: effect of hypoxic severity and role of p53 in neuronal cell death
1998
Role of the proto-oncogene Pokemon in cellular transformation and ARF repression
2005 Nature
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
2013
A Bivalent Chromatin Structure Marks Key Developmental Genes in Embryonic Stem Cells
2006 Standout
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer
2004 Standout
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
2009 Standout
Chemotherapy for advanced gastric cancer
2010
Inhibition of SIRT1 Impairs the Accumulation and Transcriptional Activity of HIF-1α Protein under Hypoxic Conditions
2012
Antidepressive-like effects of rapamycin in animal models: Implications for mTOR inhibition as a new target for treatment of affective disorders
2008
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
2004 Standout
Novel Role for JNK as a Stress-activated Bcl2 Kinase
2001
The Epigenomics of Cancer
2007 Standout
Analyzing real-time PCR data by the comparative CT method
2008 Standout
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
2004 Standout
Docetaxel in combination for advanced gastric cancer
2002
The role of new agents in the treatment of non-small cell lung cancer
2002
Intact, injured, necrotic and apoptotic cells after focal cerebral ischemia in the rat
1998
PI3K signaling of autophagy is required for starvation tolerance and virulenceof Cryptococcus neoformans
2008 StandoutNobel
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
2011 StandoutNature
Risk factors for brain relapse in patients with metastatic breast cancer
2004
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
2004 Standout
Induction of Apoptosis in HL-60 Human Promyelocytic Leukemia Cells by Adenosine A3Receptor Agonists
1996 StandoutNobel
A randomized phase 2 study of docetaxel and S‐1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy
2010
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
2006
Autophagy in the Pathogenesis of Disease
2008 Standout
Targeting RAS signalling pathways in cancer therapy
2003 Standout
PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
2007
Capecitabine: A review
2005
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
2009
EMT: 2016
2016 Standout
Understanding resistance to EGFR inhibitors—impact on future treatment strategies
2010
Polycomb-group genes as regulators of mammalian lymphopoiesis
2001
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
2005 StandoutNature
Impact of chemotherapy on quality of life in patients with metastatic esophagogastric cancer
2010
Stem Cells and Cancer
2004 Standout
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
2017 StandoutNature
Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
2011
Current strategies in the management of hormone refractory prostate cancer
2003
AKT/PKB Signaling: Navigating the Network
2017 Standout
Effective combination chemotherapy with paclitaxel and cisplatin with or without human granulocyte colony-stimulating factor and/or erythropoietin in patients with advanced gastric cancer
2002
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
2015 Standout
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial
2017
Extracellular vesicles as drug delivery systems: Lessons from the liposome field
2014
Functional Demarcation of Active and Silent Chromatin Domains in Human HOX Loci by Noncoding RNAs
2007 Standout
Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study
2002
A coding-independent function of gene and pseudogene mRNAs regulates tumour biology
2010 StandoutNature
DNA Fragmentation Follows Delayed Neuronal Death in CA1 Neurons Exposed to Transient Global Ischemia in the Rat
1997
Metastatic colonization by circulating tumour cells
2016 StandoutNature
mTOR and cancer: insights into a complex relationship
2006
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
2010 StandoutNature
Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
2008
Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial
2007
Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin Signaling
2009 Standout
Up-Regulation of the Nedd2 Gene Encoding an ICE/Ced-3-Like Cysteine Protease in the Gerbil Brain after Transient Global Ischemia
1997
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
2014
S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial
2015
Docetaxel, Cisplatin and Fluorouracil (DCF) Regimen Compared with Non-Taxane-Containing Palliative Chemotherapy for Gastric Carcinoma: A Systematic Review and Meta-Analysis
2013
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Hepatocellular Carcinoma
2019 Standout
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
2011
Chemotherapy in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis Based on Aggregate Data
2006
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
2007
Overexpression of SOD1 in Transgenic Rats Protects Vulnerable Neurons Against Ischemic Damage After Global Cerebral Ischemia and Reperfusion
1998
Phase III Study of Docetaxel and Cisplatin Plus Fluorouracil Compared With Cisplatin and Fluorouracil As First-Line Therapy for Advanced Gastric Cancer: A Report of the V325 Study Group
2006 Standout
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
2011 Standout
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Clinical Studies of Three Oral Prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): A Review
2002
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
Global Ischemia Induces Immediate-Early Genes Encoding Zinc Finger Transcription Factors
1996
Tumor Budding: The Name is EMT. Partial EMT.
2016
Chemotherapy for advanced gastric cancer
2017 Standout
Drug-Induced Neuroprotection From Global Ischemia Is Associated With Prevention of Persistent but Not Transient Activation of Nuclear Factor-κB in Rats
1998
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Subtle Neuronal Death in Striatum After Short Forebrain Ischemia in Rats Detected by In Situ End-Labeling for DNA Damage
1997
Ethanol-Induced Apoptotic Neurodegeneration and Fetal Alcohol Syndrome
2000 StandoutScience
Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease.
1999
Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis
2013
Global Ischemia Activates Nuclear Factor-κB in Forebrain Neurons of Rats
1997
Bimonthly 24 h Infusion of High-Dose 5-Fluorouracil vs EAP Regimen in Patients with Advanced Gastric Cancer
2007
Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297
2002
Phase II Multi-Institutional Randomized Trial of Docetaxel Plus Cisplatin With or Without Fluorouracil in Patients With Untreated, Advanced Gastric, or Gastroesophageal Adenocarcinoma
2005
Phase I/II Trial of Capecitabine, Oxaliplatin, and Radiation for Rectal Cancer
2003
Ischemic Cell Death in Brain Neurons
1999 Standout
Alternative RNA Splicing Produces Multiple Forms of c-Myb with Unique Transcriptional Activities
2008
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
2005
Missense mutations of the BRAF gene in human lung adenocarcinoma.
2002
Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice
2008 StandoutNobel
Superiority of Oxaliplatin and Fluorouracil-Leucovorin Compared With Either Therapy Alone in Patients With Progressive Colorectal Cancer After Irinotecan and Fluorouracil-Leucovorin: Interim Results of a Phase III Trial
2003
Efficacy of the Oral Fluorouracil Pro-drug Capecitabine in Cancer Treatment: a Review
2008
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013
Metastatic pancreatic cancer: Is gemcitabine still the best standard treatment? (Review)
2010
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer
2009
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
2006
Cryptococcus neoformansCapsular Glucuronoxylomannan Induces Expression of Fas Ligand in Macrophages
2005
Distinguishing excitotoxic from apoptotic neurodegeneration in the developing rat brain
1999
CNS Metastases in Breast Cancer
2004
Works of Markus Borner being referenced
Intratumoural budding (ITB) in preoperative biopsies predicts the presence of lymph node and distant metastases in colon and rectal cancer patients
2013
High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel
2001
Alternative Splicing of the Human Cyclin D-binding Myb-like Protein (hDMP1) Yields a Truncated Protein Isoform That Alters Macrophage Differentiation Patterns
2003
The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression
2001
Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days
1998
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
2005
UFT and leucovorin in first-line chemotherapy for patients with metastatic gastric cancer. An Early Clinical Studies Group (ECSG)/European Organization for Research Treatment of Cancer (EORTC) phase II trial
2001
Klinische Entwicklung zielgerichteter molekularer Krebstherapeutika
2005
Apoptosis: Its Role in the Development of Malignancies and its Potential as a Novel Therapeutic Target
1997
Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report
2001
Activity of Gemcitabine and Continuous Infusion Fluorouracil in Advanced Pancreatic Cancer
2000
Internucleosomal DNA fragmentation in gerbil hippocampus following forebrain ischemia
1994
Capecitabine in hormone-resistant metastatic prostatic carcinoma – a phase II trial
2004
Relationships between proto-oncogene expression and apoptosis induced by anticancer drugs in human prostate tumor cells
1995
Optimisation of irinotecan dose in the treatment of patients with metastatic colorectal cancer after 5-FU failure: results from a multinational, randomised phase II study
2005
Epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer: A multicentric phase I–II study
2000
Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK
2008
5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)–cisplatin in advanced gastric carcinoma: a phase I–II trial
2004
First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. Swiss Group for Clinical Cancer Research.
1994
Prevention of palmar–plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08)
2014
Docetaxel (Taxotere®)-cisplatin (TC): An effective drug combination in gastric carcinoma
2000
The impact of cetuximab on the capecitabine plus oxaliplatin (XELOX) combination in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
2006
Phase II Study of Capecitabine and Oxaliplatin in First- and Second-Line Treatment of Advanced or Metastatic Colorectal Cancer
2002
Docetaxel-cisplatin-5FU (TCF) versus docetaxel-cisplatin (TC) versus epirubicin-cisplatin-5FU (ECF) as systemic treatment for advanced gastric carcinoma (AGC): A randomized phase II trial of the Swiss Group for Clinical Cancer Research (SAKK)
2004
Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma
2000
Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
2010
Combining Capecitabine and Gemcitabine in Patients With Advanced Pancreatic Carcinoma: A Phase I/II Trial
2002
5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC)
1999
Phase II Study of Temsirolimus (CCI-779), a Novel Inhibitor of mTOR, in Heavily Pretreated Patients With Locally Advanced or Metastatic Breast Cancer
2005
Continuous Sunitinib Treatment in Patients with Advanced Hepatocellular Carcinoma: A Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) Multicenter Phase II Trial (SAKK 77/06)
2010
Answering Patients' Needs: Oral Alternatives to Intravenous Therapy
2001
Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research
2007
Randomized Comparative Study of Tegafur/Uracil and Oral Leucovorin Versus Parenteral Fluorouracil and Leucovorin in Patients With Previously Untreated Metastatic Colorectal Cancer
2002